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Collections of tumour samples can be an invaluable resource for medical
research. There are, however, numerous ethical and legal challenges
associated with tumour banking. While there has been extensive discussion
of these issues in the legal and ethical literature, there are few available
empirical data in relation to the activities of tumour banks in Australia, their
practices around ethically charged issues, and their success in implementing
complex regulatory guidelines. The aim of this study was to gain more
information about the activities of tumour banks in New South Wales,
Australia, with a particular focus on their management of, and attitudes
towards, ethical and regulatory issues. A survey of 27 tumour collection and
research facilities was conducted using a 55-item questionnaire. There is
significant heterogeneity of research methodologies as well as of methods for
gaining consent and ensuring donor privacy, and there is general concern
among the research community about ethical and regulatory issues related to
tumour banking. Heterogeneity of practice and uncertainty about ethical and
regulatory requirements is problematic in its potential to hinder research and
its potential to generate the space for unethical practice, whether intentional
or unintentional. There is a pressing need to address these issues so that
tumour banks can be used in the most ethical and efficient way possible.
INTRODUCTION
Collections of stored tumour samples removed during diagnostic or therapeutic procedures are an
invaluable resource for medical research. These collections or “tumour banks” are particularly
valuable for molecular, genetic and immunopathological investigation of the aetiology, prognosis and
management of cancer.1 Molecular techniques involving tissue micro-arrays, laser capture microscopy
and adaptations of mass spectrometry, together with new information technology tools, have the
potential to shed light on tumour aetiology, classification (in relation to other neoplasms), and
* Dr Georgina Clark, BA (Hons), MA, MBBS (Hons), Centre for Values Ethics and the Law in Medicine, University of Sydney;
Dr Wendy Lipworth, MA, MBBS, Centre for Values Ethics and the Law in Medicine, University of Sydney; Professor Les
Bokey, MS, MBBS, FRACS, Department of Surgery, Repatriation General, Concord, University of Sydney;
Professor Emeritus JM Little, MS, FRACS, MD, FRSM, Centre for Values Ethics and the Law in Medicine, University of
Sydney; Associate Professor Ian H Kerridge, BA, BMed (Hons), MPhil, FRACP, FRCPA, Director, Centre for Values Ethics and
the Law in Medicine, University of Sydney.
The authors wish to acknowledge: the participation of all survey respondents; Lindy Gaze for her enthusiastic support of the
project; Dr Daniel Catchpoole, Tumour Bank Manager at the Children’s Hospital, Westmead, for his extensive support of the
project; Professor Donald Chalmers, Centre for Law and Genetics, University of Tasmania, for his generosity in sharing his
compiled list of tissue banks; and Mr John McPhee, Centre for Values Ethics and the Law in Medicine, University of Sydney,
for his assistance with data analysis. This research was funded by the University of Sydney Cancer Research Fund and was
approved by the University of Sydney Human Research Ethics Committee. No competing interests were identified for any of the
authors.
Correspondence to: Dr Georgina Clark, Centre for Values Ethics and the Law in Medicine, Blackburn Building DO6, University
of Sydney, NSW 2006, Australia.
1 Australian Law Reform Commission, Essentially Yours: The Protection of Human Genetic Information in Australia, Report 96
(Commonwealth of Australia, Canberra, 2003); Oosterhuis J, Coebergh J and Veen EV, “Tumour Banks: Well-guarded
Treasures in the Interest of Patients” (2003) 3 (1) Nature Reviews Cancer 73.
(2006) 14 JLM 102102©
treatment responsiveness. Whilst the above techniques can be applied to single samples, tissue
banking of specimens greatly enhances the power of translational research. The banking of numerous
samples enables epidemiologically sound correlations to be made. Moreover, storage over time
enables laboratory findings to be correlated with tumour progression and patient responses, as well as
enabling as yet undiscovered techniques to be applied to samples collected today.
The collection, storage and use of tissue for research presents a number of technical, ethical and
regulatory challenges. While it is important to facilitate the progress of research, it is also important to
protect the interests of tissue donors and of the communities of which they are a part. This may require
that the tissue is used only with the donor’s consent and only for research that is acceptable to them.2
In addition, it may also be necessary to protect donor privacy,3 particularly as advances in genomic
research allow greater insight into a donor’s present and future health risks as well as the health status
of the donor’s family and community. Protection of donor interests in these ways not only satisfies
contemporary ethical and legal standards but encourages public trust in the research process and can
be an important element of ongoing public commitment to research efforts, and willingness to donate
tissue. The fragility of public trust in the research endeavour, and in research involving retained tissue,
in particular, has been highlighted by the impact of recent national and international “tissue retention
scandals”.4
While few would argue against the need for regulation of research involving human tissue, the
increased public scrutiny of tissue research practices, along with more stringent personal privacy and
human tissue legislation, have created an increasingly complex network of regulations around tissue
banking. For example, tumour banks in New South Wales must comply with numerous legislative and
regulatory requirements, including the following:
• the common law relating to assault and confidentiality;
• Privacy Act 1988 (Cth);
• Privacy and Personal Information Act 1998 (NSW);
• Health Records and Information Privacy Act 2004 (NSW);
• Human Tissue Act 1983 (NSW);
• National Health and Medical Research Council’s National Statement on the Ethical Conduct of
Research Involving Humans;
• Royal College of Pathologists of Australia (RCPA) policy statement on the secondary use of
human tissue samples collected for diagnostic purposes;
• National Health and Medical Research Council, Guidelines for Genetic Registers and Associated
Genetic Material;
• Human Genetics Society of Australasia, Guidelines for Human DNA Banking;
• NSW Health, Information Privacy Code of Practice;
• Human Genetics Society of Australasia and Royal Australasian College of Physicians, Policy
Statement on the Retention, Storage and Use of Sample Cards from Newborn Screening
Programs;
• NSW Health, Requirements of the Human Tissue Act 1983 in Relation to Research Utilising
Human Tissue: Guidance for Human Research Ethics Committees; and
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BMJ 648; Salvulescu J, “No Consent Should be Needed for Using Leftover Body Material for Scientific Purposes. Against”
(2002) 325 BMJ 648.
3 Gaze B, “Privacy and Research Involving Humans” (2003) 10 JLM 410; Caulfield T, “Tissue Banking, Patient Rights and
Confidentiality: Tensions in Law and Policy” (2004) 23 Medicine and Law 39; Korn D, “Dangerous Intersections: New
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Science and Technology 55.
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• National Pathology Accreditation Advisory Council, Guidelines for the Retention of Laboratory
and Diagnostic Material.5
The concern that many researchers have is that this regulatory complexity may adversely impact
upon the progress of cancer research in Australia. At present, however, there are few empirical data
about the impact of the regulatory environment on tumour banking research. Furthermore, there is
little information about how scientists and administrators perceive and address the ethical and legal
challenges associated with tumour banking. This aim of this study was to provide an overview of
tumour banking research in New South Wales and to describe the practical, ethical and regulatory
concerns expressed by researchers.
PARTICIPANTS AND METHODS
There is currently no comprehensive registry of tissue banks in Australia. Consequently, the authors
compiled a list of tumour banks through internet searches, from existing lists of tissue banking
facilities collated by previous Australian researchers, through listings of identifiable health services’
tumour banks, through listings of the Australasian Biospecimens Network membership, and through
snowball sampling. Twenty-seven appropriate tumour banks were identified. While the intention was
to develop as comprehensive a list of tumour banks as possible, in the absence of an existing register
of tumour banks it is likely that some banks may have been inadvertently excluded from the sample.
Nonetheless, it is the authors’ belief that this list is representative of the range of research institutions
involved in tumour collection and research, including public research institutions, cancer institutes,
pathology laboratories and private research institutions.
A 55-item survey tool was developed by the research team at the Centre for Values Ethics and the
Law in Medicine (CVELIM). This was based on a taxonomy of tumour banking activities developed
previously at the Centre.6 The survey included questions about demographics, research activities, data
storage and donor privacy, consent procedures, administrative and regulatory processes, funding, and
the difficulties that researchers reported in relation to meeting ethical and regulatory standards. The
survey instrument was developed in consultation with tumour bank researchers to ensure coherence,
content validity and scope, and was piloted with representative stakeholders to clarify format, wording
and face validity.
The self-response surveys were mailed in July 2005 to 27 research groups known to be involved
in cancer research and to have tumour sample collections Surveys were addressed to senior members
of the research organisation who were likely to have an understanding of both the scientific and
managerial aspects of tumour bank practice. A follow-up survey was mailed to non-responders one
month later and follow-up reminder calls were made, where necessary. A total of 17 responses were
received, representing a response rate of 63%.
RESULTS
Tumour bank demographics and activities
All groups surveyed use their tumour sample collections for research. Additionally, 12% of
respondents used their collections for educational purposes. No respondents reported using their
collections for development of commercial products, and no respondents reported being involved in
non-medical testing (eg law enforcement, insurance).
All of the tumour research collections were established post-1983. Half were established since
1998, and more than a third were established in the last two years.
There was a wide range in the size of collections, from those with less than 10 samples to those
with up to 20,000 samples. The median number of samples was 350. There was also a wide range in
the rate of collection, with one bank collecting about 2,000 samples a year. The average collection rate
was 111 samples per year.
5 See Lipworth W, “Navigating Tissue Banking Regulation: Conceptual Frameworks for Researchers, Administrators,
Regulators and Policy-makers” (2005) 13 JLM 245 at 247-248.
6 Lipworth, n 5.
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A variety of tissue types were collected, including adrenal gland, bladder, bone, breast, brain,
cervix, colorectal, endometrium, fallopian tube, glioma, head and neck, kidney, leukaemia, liver,
lymphomas, ovary, pancreas, prostate, pituitary, skin, testes and thyroid. The most commonly reported
type of tumour samples were leukaemia and breast, brain, colorectal and ovarian cancers. A total of
47% of respondents collected tissue samples of diseases other than cancer in addition to tumour
samples and 88% of respondents collected normal (non-pathological) tissue. Most commonly, this
normal tissue consisted of blood samples or non-pathological correlates of tumours of interest (eg
normal breast for breast cancer studies).
Research activities
A range of different types of research were conducted using the banked samples. A total of 82% of
respondents conducted research into the aetiology of cancer, 53% into diagnostic methods and tools,
41% into treatments, and 18% into normal biology and physiology. The majority of this research used
molecular, proteomic and cytogenetic techniques, with histopathological and immunophenotic
research methods being utilised less often.
A total of 65% of respondents reported performing genetic/genomic studies using their banked
samples. These included:
• linkage studies, to identify the gene sequences associated with inherited diseases (n=12%);
• association studies, to find correlations between a disease and a genetic change where there is no
obvious pattern of inheritance (n=47%);
• genetic epidemiology studies, to identify the interaction between genes and environment
(n=12%); and
• pharmacogenetic studies, to determine if there is a genetic basis for responsiveness to drugs or to
adverse drug reactions (n=24%).
Privacy and data storage
All tumour banks surveyed had mechanisms in place to protect data privacy. The vast majority of
research facilities de-identified tumour samples with 82% retaining a coded link between the sample
and the donor, making re-identification possible. A small number (6%) of facilities did not de-identify
or anonymise tumour samples at any point.
A total of 65% of respondents said that their bank linked samples to a health record database to
track donor patient outcomes. Third-party access to written and/or computer records relating to
samples was reported by 18% of respondents, although in no case did third parties include insurance
companies, law enforcement groups or financial sponsors.
Research groups reported collecting the following information about samples and/or donors:
• demographic information (77%);
• diagnostic information (71%);
• exposure and lifestyle information (24%);
• family history data (41%);
• histopathological data (65%);
• recurrence data (59%);
• research results (47%);
• genetic profile (eg genomic information) (41%); and
• treatment data (53%).
Consent
In relation to current practice, all respondents reported obtaining consent for the collection, storage
and research use of samples. However, 47% of respondents reported that there were samples in their
collections that had been collected in the past without consent being obtained for research purposes
(eg in archival collections).
Respondents were asked to identify what model of consent was commonly used in their facility.
They were asked indicate which of the following models of consent they used:
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• blanket consent, where a donor gives consent for the use of their tissue sample for research in
general, ie the exact research uses are unspecified, and it is therefore generally understood that the
consent allows for the use of the sample in almost any type of research at the discretion of the
tissue bank;
• project-specific consent, where a donor gives consent for the use of their tissue sample for a
single specific research project, ie for investigating a specified research question at a specified
research facility; or
• categorical consent, where a donor gives consent for the use of their tissue sample in a specific
category of research, eg the donor may give consent to research into a particular disease, or
research for a particular treatment, or research by a particular group, but not to research in general
and not only to a single specified project.
Table 1 lists the types of consent given.
TABLE 1 Types of consent given
Type of consent Percentage of respondents
Blanket consent only 47%
Project-specific consent only 24%
Categorical consent only 29%
Donors have the opportunity to decide whether they would
like to give blanket consent, project-specific consent or
categorical consent
6%
Over 70% of respondents reported that their donors are not given the opportunity to specify
whether they would like to be recontacted in future, should the tumour bank wish to obtain further
consent for new projects.
A total of 59% of respondents reported that their donors are informed of how long samples will be
stored. Only 29% of respondents said donors are informed of who owns the sample once it is donated.
Less than half (47%) of respondents reported that donors are given an indication of whether or not
they will receive a portion of profits should research lead to a commercial product. A total of 88% of
respondents reported that their donors are given information about the likelihood, or lack thereof, of
direct benefits from involvement in research, while 82% of respondents said donors are given
information on the potential risks associated with donation (eg possibility of breach of confidentiality).
A total of 82% indicated that donors are informed that samples might be used in genetic research.
Respondents reported using a number of different approaches for dealing with situations where
researchers sought access to samples where consent for future research had not explicitly been
obtained from the donor. These include:
• recontacting the donor and obtaining consent for the research project under consideration (35%);
• presuming consent (24%); and
• seeking consent from a third party (18%).
In cases where consent was gained from a third party, this was most often from a close relative (47%)
or from an institutional research ethics committee (24%). No respondents reported obtaining
third-party consent from a community representative. The most common reason for seeking consent
from a third party was:
• the donor was deceased (29%);
• the donor could not be located or contacted (18%);
• the donor was a minor (12%); and
• the donor was judged to be too ill to give consent (6%).
A total of 24% of banks reported not using samples for research purposes unless consent to future
research had been explicitly obtained at the time of tissue donation.
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Disposal and ownership
In relation to perceived ownership of tissue samples, 77% of respondents stated that tissue samples
were the property of the tumour bank or the hospital while 12% reported that the samples were owned
by the donor. In no case did respondents believe that samples were owned by financial sponsors of
research.
Respondents reported a number of different approaches to the disposal and return of tissue
samples:
• 41% reported that samples were discarded or destroyed following the completion of research;
• 6% of samples were retained in long-term storage;
• 6% were returned to diagnostic pathology services; and
• 35% had no specified management plan for the return or disposal of tissue samples.
No respondents reported returning samples to donors.
Disposal/return most commonly occurred when there was no longer sufficient tissue to carry out
further research (53%) or when the research project was completed (12%).
Ethical oversight of research involving banked specimens
All respondents reported that research done within their institution using tumour samples was subject
to the approval of the relevant Human Research Ethics Committee (HREC).
In the majority of cases, samples were accessible to researchers from other institutions (n=71%).
Where researchers from external institutions sought access to samples for research, in all cases
respondents indicated that this research had to be approved by a HREC, either at the institution where
the bank was located (n=6%), at the external researcher’s institution (n=41%), at either institution
(n=12%) or at both institutions (n=41%).
Administration and community participation
Tumour banks had a range of administrative structures and frequently were linked to multiple
institutions including universities and hospitals:
• 94% of tumour banks reported were located within a larger research institution;
• 35% were linked to a hospital or health service; and
• 41% were linked to a university.
No respondents reported being part of a commercial/private enterprise.
A total of 65% of respondents had an advisory committee. The composition of advisory
committees included researchers (59%), clinicians (59%), lawyers (12%), and community representa-
tives (12%). No advisory boards included ethicists.
A total of 41% of tumour banks had a process for community participation (eg feedback to donors
about the research activities of the bank). The most common forms of communication with the
“community” were newsletters and websites, while 18% of banks had in place processes whereby
community representatives could provide input into the direction or mission of the tumour bank,
including having advocacy or consumer group representation on the advisory board.
Funding
The vast majority of tumour banks reported receiving funding from federal (53%) or State (41%)
government grants. Other sources of funding included hospital funds (47%), university grants (29%),
and less often cancer foundations, benevolent foundations, trust funds and philanthropic donations. No
funding support was received by 6% of respondents.
Attitudes towards regulation
A total of 71% of respondents felt that there is an appropriate amount of ethical oversight of tumour
banking practice. The remainder felt that there was too much ethical oversight of tumour banking
practice and no respondents felt that there was insufficient regulation.
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A total of 59% of respondents felt that ethical oversight of tumour banking practice is sufficiently
informed, while 71% reported that in their experience, HRECs varied in their interpretation of ethical
and/or legal requirements around gaining consent for research involving tumour bank samples.
Tumour banks used a variety of sources for advice on how to navigate tumour banking regulatory
obligations. Most commonly accessed sources were:
• HRECs (94%);
• the research community (59%);
• advisory boards to tumour banks (53%); and
• the National Health and Medical Research Council (NHMRC) (59%).
Other sources included administration research offices, the Australasian Biospecimens Network,
lawyers, the Department of Health Ethics Branch, and the Australian Health Ethics Committee
(AHEC).
When asked what they believe would be most helpful in facilitating tumour bank research, the
most common suggestions were:
• simplification of legislation governing tumour banking (71%);
• increased provision of funding to tumour banks (82%); and
• establishment of a centralised ethics committee for consideration of research involving tumour
banks (71%).
A total of 53% advocated the provision of more information, education and guidance on regulatory
requirements from bodies such as AHEC and NHMRC, while 29% supported consolidation of samples
within larger banks or facilities and 29% advocated the establishment of professional advisory boards
to provide guidance on processes for administration of tumour banks. Some respondents advocated
greater cooperation between tumour banks.
DISCUSSION
This study confirms that tumour banking is extensively practised in New South Wales and that there
has been an exponential growth of tumour banking in the last 10 years. These banks collect a range of
tissues and perform important research into aetiology, diagnosis, prognosis and management of cancer
using a number of established and emerging methodologies. There is, however, significant variation in
the administration of tumour bank research and it appears that there is ongoing uncertainty regarding
the processes necessary to meet ethical and legal requirements for appropriate conduct of research.
This research is valuable because it provides the first detailed, descriptive, account of tumour
bank activity in New South Wales. The high response rate and self-report nature of the survey suggest
that the results are likely to provide an accurate insight into research using stored tissues There are,
however, a number of limitations to this research. First, since this study used a self-report instrument,
this research is open to the possibility of social desirability bias and interpretive error. Second, the
generalisabilty of the data is open to contest as the sample was limited to New South Wales and it is
possible that some tumour banks were inadvertently excluded due to the absence of a comprehensive
register of research facilities. Finally, as this research reports only the results of a survey, it cannot
adequately capture the complexity of the ethical and legal issues surrounding consent, privacy,
community participation and appropriateness of regulation. This would require the use of qualitative
methodologies such as in-depth interviews or focus groups. This is the focus of ongoing research.
It is reassuring to note that all tumour banks seek consent for storage and use of samples in
research. There is, however, significant heterogeneity in consent processes, suggesting that there may
be a need for clearer guidance as to which consent processes are most appropriate in a range of
situations. While the lack of consistency regarding consent methods is not necessarily a problem, it is
of some concern that a large number of donors do not appear to be informed about the ownership of
samples, the commercial utilisation of samples, the retention and disposal of samples, and the risks
associated with the research, particularly related to potential breaches of confidentiality. This is
particularly important given that 82% of tumour banks have processes whereby samples could
conceivably be re-identified. It is worth noting, however, that the results of the research suggest that
the risks associated with donating tumour samples for research are likely to be small because samples
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are almost always de-identified (coded), no banks provide access to third parties who do not have a
direct research interest and, in all cases, access to samples for research purposes is overseen by
research ethics committees.
While all tumour banks reported an administrative structure that involved scientific and advisory
groups, few banks provide opportunity for community involvement and participation. Also, many
banks do not have processes for communicating with donors, communities of donors and the wider
community. Given the fragility of public trust in science and medical research, the authors believe that
the lack of serious attention paid to community participation and the failure to establish adequate
processes for providing information represent serious failures in the current organisation of tumour
banking research and offer real opportunities for improvement.
In general, respondents to this survey indicated that they felt that there was an appropriate amount
of ethical oversight of tumour banking. While this suggests that researchers recognise the need for
ethical and legal oversight, there are concerns about regulatory processes. The present results suggest
that regulation of tumour banking research may be improved and made less burdensome by the
provision of simple, clear and uniform guidance regarding ethical and legal requirements and through
consideration of means to simplify and streamline existing privacy and human tissue legislation. The
results also suggest that there may be significant support for specific measures, such as the
establishment of centralised ethics committees for the consideration of tumour banking research.
CONCLUSION
It is apparent that there is ongoing uncertainty regarding the appropriate processes by which tumour
banks should be established and administered. This is highly problematic for researchers, donors,
administrators and sponsors as it has the potential to hinder research, entrench unethical practice and
thus threaten the entire cancer research endeavour. There is a pressing need to clarify the ethical and
regulatory issues surrounding tumour banking and to place tumour banks within a broader research
and social context. Tumour banking research does not occur in isolation either from health care or
from other types of medical research, and as such all members of the community have an interest in its
conduct and outcomes.
It is widely anticipated that the recently established Human Genetics Advisory Committee
(HGAC), which has been formed to advise government on the social, ethical and legal implications of
human genetic and related technologies, will review the processes of tissue banking, particularly those
related to consent.7 It is the authors’ hope that the HGAC will also consider some of the other issues
raised by tumour banking research, particularly the means by which communities can engage in both
determining the direction of research and in the construction of policies regarding its conduct and
organisation.
7 See NHMRC website brief on the Human Genetics Advisory Committee: http://www.nhmrc.gov.au viewed 1 May 2006.
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